Abstract Background Inclisiran is a small interfering RNA (siRNA) that interferes with the production of proprotein convertase subtilisin kexin type 9 (PCSK9). This results in the lowering of circulating low-density lipoprotein cholesterol (LDL-C). In clinical trials inclisiran showed effective lowering of LDL-C reduction of ± 50 %. Purpose We sought to analyse the data from the first 55 patients to be initiated on inclisiran in a cardiology secondary prevention clinic to establish whether this addition to standard lipid therapy could improve compliance with European lipid targets. Methods We collected and analysed data on every patient who was initiated on inclisiran in the clinic during a period of 16 months from March 2024. Baseline lipid profiles were taken prior to initiation to ensure criteria was met and further profiles requested at 3 months and 5 months. A target level of LDL-C 1.4mmol/L was used as defined by the European Society of Cardiology (ESC) 2021 guidelines. Results At 16 months there was an average decrease in total cholesterol levels of 33%, non-HDL-C levels of 44% and LDL-C levels of 49%, with 41% of patients now meeting lipid targets for LDL-C as defined by ESC. Conclusion In a real-world setting, the addition of inclisiran to maximally tolerated lipid therapy can significantly reduce LDL-C levels and improve compliance with lipid targets when used in line with ESC guidelines.
Smith et al. (Mon,) studied this question.